Oncimmune Limited

Oncimmune aims to develop EarlyCDT-Lung+ as a test to help with the earlier identification of lung cancer in patients with indeterminate pulmonary nodules (IPNs). The resulting new blood test will enable the stratification of higher risk IPNs and ensure those patients at higher risk of malignancy receive further interventions, such as PET-CT, or endobronchial ultrasound supported biopsy to diagnose the cancer as early as possible.

The project will combine Oncimmune’s capabilities in project management and data analysis with health economics and patient involvement at University of Leeds and biochemistry from Leeds Teaching Hospitals NHS Trust.